

MEDICAL
SYMPOSIUM

INFLUENCING THE LANDSCAPE
OF DEMENTIA CARE

alzheimer's  association™

A MEETING

OF THE

MINDS

DEMENTIA CONFERENCE 2010

RiverCentre, St. Paul, Minnesota

Saturday, March 20, 2010



DISCLOSURE AND CONFLICT OF INTEREST (COI RESOLUTION)

The following tables contain disclosure information for all individuals in a position to control the content of this CME activity and must be presented to learners prior to AMDA Jointly Sponsored Education Activities. When there were no relevant financial relationships to disclose, "No Relationship" will appear in the "Financial Relationships" column. Where relevant financial relationships have been disclosed, efforts have been made to resolve any conflict of interests. Please see the description of the methods of conflict resolutions used as shown below under "Methods of Resolution for Conflicts of Interest."

DISCLOSURE TABLE 1

PLANNING COMMITTEE MEMBER	FINANCIAL RELATIONSHIPS
J. Riley McCarten, MD	No Conflicts
Susan McPhersen, PhD, ABPP, LP	No Conflicts
Ronald Petersen, MD, PhD	Elan Pharmaceuticals, Chair, Safety Monitoring Committee and Consultant; Wyeth, Chair, Safety Monitoring Committee; GE Healthcare, Consultant
Edward Ratner, MD	No Conflicts
George Schoepfoester, MD	No Conflicts
John Selstad	No Conflicts

DISCLOSURE TABLE 2

FACULTY MEMBER	FINANCIAL RELATIONSHIPS
Bradley Boeve, MD	Myriad Pharmaceuticals: investigator, clinical trials; Cephalon, Inc.: investigator, clinical trials; GE Healthcare: consultant; American Academy of Neurology: received honoraria; Cambridge Medicine: book royalties, Behavioral Neurology of Dementia, 2009; National Institute on Aging, Center for Inherited Disease Research and the Alzheimer's Association: research support. Dr. Boeve may discuss use of several medications that are not FDA-approved for the indications that are reviewed, which may include discussions on melatonin, clonazepam, cholinesterase inhibitors, carbidopa/levodopa, dopamine agonists, selective serotonin reuptake inhibitors, atypical neuroleptics, lithium, glycogen synthase kinase-3 beta inhibitors, tau aggregation inhibitors, anti-amyloid immunotherapies, memantine, sedative/hypnotics and psychostimulants for the management of cognitive impairment, neuropsychiatric disorders, parkinsonism, sleep disorders and autonomic dysfunction.
Charles Denny, Jr.	No Conflicts
Steven DeKosky, MD	Eisai: Consultant, drug development; Psychogenics, Inc.: Consultant, preclinical drug development; Pfizer: Advisory Board, Academic Medical Center-Pharma Relationships; Merck: Consultant, Drug Development; United Medical Corp.: Consultant, Neurological Services; Wyeth: Consultant, Drug Development; Novartis: Consultant: Drug Development; Up to Date (electronic medical test), Editor for Neurodegenerative Disorders
Robert Egge	No Conflicts
J. Riley McCarten, MD	No Conflicts
Ronald Petersen, MD, PhD	See above for Financial Relationships
Mark Sager, MD	No Conflicts
Jeffrey Schiff, MD, MBA	No Conflicts
David Weimer, PhD	No Conflicts

UNAPPROVE USE DISCLOSURE

The American Medical Directors Association (AMDA) requires CME faculty (speakers) to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty at this symposium may/will discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

DISCLAIMER

The information provided at this CME/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.

CONTINUING MEDICAL EDUCATION

Accreditation Statement: The Medical Symposium has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the American Medical Directors Association (AMDA) and the Minnesota Medical Directors Association. The American Medical Directors Association is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement for all CME activities: The American Medical Directors Association designates this educational activity for a maximum of 4 AMA PRA Category 1 Credit(s)[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Certified Medical Directors Credit Statement: This seminar has been approved for a total of 4 credits toward certification as a Certified Medical Director in Long-Term Care (CMD). 3.5 credits have been designated as Management hours and .5 credits have been designated as Clinical hours. The AMDA CMD program is administered by the American Medical Directors Certification Program. Each physician should claim only those hours of credit actually spent on the activity.

MEDICAL SYMPOSIUM

INFLUENCING THE LANDSCAPE OF DEMENTIA CARE

STATEMENT OF NEED

Advances in research offer a glimpse into the future of Alzheimer's diagnostics and potential primary and secondary interventions. Yet, the vision of a healthcare system that can provide quality diagnosis, treatment and care to the 10 million baby boomers expected to have this disease is still unclear. The Medical Symposium will draw on the expertise of practitioners and thought leaders to highlight current and innovative models in dementia diagnosis and treatment, as well as existing challenges and pitfalls of dementia care.

TARGET AUDIENCE

Physicians, neuropsychologists, physician assistants, nurse practitioners and other dementia medical team members

MEDICAL SYMPOSIUM SCHEDULE AT A GLANCE

7:45 – 8:30 am	Registration / Exhibits Open / Continental Breakfast
8:30 – 10:35 am	Welcome and Opening Keynote: The Rock Stars of Science – Live on Stage! Steven T. DeKosky, MD, FACP, University of Virginia Ronald Petersen, MD, PhD, Mayo Clinic

MEDICAL SYMPOSIUM SYLLABUS

10:45 – 11:00 am	Welcome
11:00 – 11:30 am	The Road Ahead in MCI and Alzheimer's Disease Diagnosis, Treatment & Prevention Ronald Petersen, MD, PhD, Mayo Clinic
11:30 – 12:30 pm	Social and Fiscal Outcomes of Early Identification David Weimer, PhD, University of Wisconsin - Madison Mark Sager, MD, University of Wisconsin - Madison
12:30 – 1:00 pm	Lunch Break / Exhibits Open
1:00 – 2:00 pm	The Local and National Impact of Healthcare Reform on Dementia Care Robert Egge, Alzheimer's Association Jeffrey Schiff, MD, MBA, State of Minnesota
2:00 – 2:15 pm	Break / Exhibits Open
2:15 – 3:45 pm	Influencing Current and Future Care Bradley Boeve, MD, Mayo Clinic – Discussant J. Riley McCarten, MD, Veterans Affairs Medical Center, University of Minnesota – Discussant George Schoephoerster, MD, Geriatric Services of Minnesota – Discussant Charles M. Denny, Jr., Caregiver, Chair, Minnesota Alzheimer's Disease Working Group – Facilitator
3:45 – 4:00 pm	Closing

SYMPOSIUM OBJECTIVES

THE ROAD AHEAD IN MCI AND ALZHEIMER'S DISEASE DIAGNOSIS, TREATMENT & PREVENTION

Ronald Petersen, MD, PhD

Mayo Clinic College of Medicine

At the conclusion of this session, the participant will be able to:

- Identify the future direction of diagnosis and treatment of patients with MCI and Alzheimer's disease.
- Define primary and secondary prevention in dementia care.

SOCIAL AND FISCAL OUTCOMES OF EARLY IDENTIFICATION

Mark Sager, MD and David Weimer, PhD

University of Wisconsin – Madison

At the conclusion of this session, the participant will be able to:

- Identify the social and practical outcomes of early identification.
- Describe the implications of the Wisconsin experience with early identification in primary care.
- Describe the fiscal outcomes of early identification.

THE LOCAL AND NATIONAL IMPACT OF HEALTHCARE REFORM ON DEMENTIA CARE

Robert Egge

Alzheimer's Association, Washington, DC

Jeffrey S. Schiff, MD, MBA

Medical Director, Minnesota Health Care Programs

At the conclusion of this session, the participant will be able to:

- Identify dementia and healthcare reform issues at the national level.
- Understand the medical home and its impact on dementia care.

INFLUENCING CURRENT AND FUTURE CARE

Bradley Boeve, MD

Mayo Clinic College of Medicine

J. Riley McCarten, MD

Veterans Affairs Medical Center, University of Minnesota

George Schoephoerster, MD

Geriatric Services of Minnesota

Charles M. Denny, Jr.

Caregiver, Chair of Minnesota Alzheimer's Disease Working Group

At the conclusion of this session, the participant will be able to:

- Describe the Minnesota Alzheimer's Disease Working Group.
- Identify the key changes necessary for improving dementia care.

SPECIAL THANKS

Jointly sponsored by:



Dedicated To Long Term Care Medicine

and the Minnesota Medical Directors Association.

AMA PRA Category 1 Credit(s)TM for physicians attending the Medical Symposium has been underwritten in memory of Ray Jost, Maidee Golden and Morris Golden.

We would like to thank the Medical Symposium planning committee. We would also like to thank Angela Lunde of Mayo Clinic, and Michelle Barclay of the Alzheimer's Association as well as the members of the Alzheimer's Association Medical and Scientific Advisory Council.